Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin as adjunct therapy for major depressive disorder
IRCT20200805048313N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in major depressive disorder (MDD), sponsored by Alborz University of Medical Sciences. Started Apr 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20200805048313N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200805048313N1.